Literature DB >> 33917660

Tumor-Treating Fields Therapy for Pediatric Brain Tumors.

Atsushi Makimoto1,2, Ryo Nishikawa3, Keita Terashima4, Jun Kurihara5, Hiroyuki Fujisaki6, Satoshi Ihara7, Yoshihiko Morikawa2, Yuki Yuza1.   

Abstract

Tumor-treating fields (TTFields) are alternating electric fields applied continuously to the brain by attaching two-pair arrays on the scalp. Although TTFields therapy has demonstrated efficacy against supratentorial glioblastoma (GBM) in adults, its safety and efficacy in children have not been confirmed. Despite differences in the genetic etiology of the adult and pediatric forms of GBM, both have certain clinical behaviors in common, allowing us to test TTFields therapy in pediatric GBM. Recently, several, pediatric case-series using TTFields therapy have been published, and a few, prospective, pediatric studies are ongoing. Because GBMs are extremely rare in pediatric patients, where they comprise a wide variety of genetic subtypes, these pediatric studies are feasibility studies targeting various types of malignant brain tumor. Although they are important for confirming the safety and feasibility of TTFields therapy in the pediatric population, confirming its efficacy against each type of pediatric brain tumor, including the GBM, is difficult. Our clinical research team, therefore, planned an investigator-initiated clinical trial targeting pediatric supratentorial GBMs (as in adults) with the aim of expanding regulatory approval of TTFields therapy for pediatric GBM treatment based on safety and exploratory efficacy data in combination with the accumulated evidence on adult GBMs.

Entities:  

Keywords:  TTFields; clinical trial; glioblastoma; pediatric brain tumors; tumor-treating fields

Year:  2021        PMID: 33917660     DOI: 10.3390/neurolint13020015

Source DB:  PubMed          Journal:  Neurol Int        ISSN: 2035-8385


  29 in total

1.  Bioelectrorheological model of the cell. 5. Electrodestruction of cellular membrane in alternating electric field.

Authors:  P Pawłowski; I Szutowicz; P Marszałek; M Fikus
Journal:  Biophys J       Date:  1993-07       Impact factor: 4.033

2.  First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.

Authors:  Daniel O'Connell; Violet Shen; William Loudon; Daniela A Bota
Journal:  CNS Oncol       Date:  2016-12-05

3.  Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

Authors:  Maciej M Mrugala; Herbert H Engelhard; David Dinh Tran; Yvonne Kew; Robert Cavaliere; John L Villano; Daniela Annenelie Bota; Jeremy Rudnick; Ashley Love Sumrall; Jay-Jiguang Zhu; Nicholas Butowski
Journal:  Semin Oncol       Date:  2014-09-16       Impact factor: 4.929

4.  Disruption of cancer cell replication by alternating electric fields.

Authors:  Eilon D Kirson; Zoya Gurvich; Rosa Schneiderman; Erez Dekel; Aviran Itzhaki; Yoram Wasserman; Rachel Schatzberger; Yoram Palti
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

5.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

6.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew A Kanner; Santosh Kesari; David M Steinberg; Steven A Toms; Lynne P Taylor; Frank Lieberman; Antonio Silvani; Karen L Fink; Gene H Barnett; Jay-Jiguang Zhu; John W Henson; Herbert H Engelhard; Thomas C Chen; David D Tran; Jan Sroubek; Nam D Tran; Andreas F Hottinger; Joseph Landolfi; Rajiv Desai; Manuela Caroli; Yvonne Kew; Jerome Honnorat; Ahmed Idbaih; Eilon D Kirson; Uri Weinberg; Yoram Palti; Monika E Hegi; Zvi Ram
Journal:  JAMA       Date:  2015-12-15       Impact factor: 56.272

7.  Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

Authors:  Giovanni L Ceresoli; Joachim G Aerts; Rafal Dziadziuszko; Rodryg Ramlau; Susana Cedres; Jan P van Meerbeeck; Manlio Mencoboni; David Planchard; Antonio Chella; Lucio Crinò; Maciej Krzakowski; Jörn Rüssel; Antonio Maconi; Letizia Gianoncelli; Federica Grosso
Journal:  Lancet Oncol       Date:  2019-10-15       Impact factor: 41.316

8.  Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis.

Authors:  Eun Ho Kim; Hyo Sook Song; Seung Hoon Yoo; Myonggeun Yoon
Journal:  Oncotarget       Date:  2016-10-04

9.  Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma.

Authors:  Edwin Lok; Pyay San; Olivia Liang; Victoria White; Eric T Wong
Journal:  J Neurooncol       Date:  2020-01-27       Impact factor: 4.130

10.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

Authors:  Quinn T Ostrom; Nirav Patil; Gino Cioffi; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2020-10-30       Impact factor: 12.300

View more
  4 in total

Review 1.  Essential Management of Pediatric Brain Tumors.

Authors:  Katharina Lutz; Stephanie T Jünger; Martina Messing-Jünger
Journal:  Children (Basel)       Date:  2022-04-02

2.  The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV.

Authors:  Aleksandrs Krigers; Daniel Pinggera; Matthias Demetz; Lisa-Marie Kornberger; Johannes Kerschbaumer; Claudius Thomé; Christian F Freyschlag
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

3.  Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data.

Authors:  Stewart Goldman; Ashley Margol; Eugene I Hwang; Kazuhiro Tanaka; Bogdana Suchorska; John R Crawford; Santosh Kesari
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

4.  Childhood brain tumors: It is the child's brain that really matters.

Authors:  David A Walker
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.